Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.
www.marketwatch.com
#biotech #stocks #hammered #shocking #brittlebone #treatment #study #results
These biotech stocks are getting hammered by shocking brittle-bone treatment study results
